Magnetic Resonance Tumour Regression Grade as Biomarker for Stratified Management of Rectal Cancer Patients
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This trial evaluates a novel imaging method called magnetic resonance tumour regression grade
(mrTRG) to assess how well a tumour has responded to chemoradiotherapy in patients with
rectal cancer. The TRIGGER Trial aims to evaluate mrTRG as a tool for stratifying the
management of patients according to their response to treatment.